American Journal of Kidney Diseases
Volume 51, Issue 5 , Pages 713-716 , May 2008

Targeting Proteinuria as a Valid Surrogate for Individualized Kidney Protective Therapy

  • Dick de Zeeuw, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Dick de Zeeuw, MD, Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

References 

  1. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy (The Collaborative Study Group). N Engl J Med. 1993;329:1456–1462
  2. No authors listed Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy (The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)). Lancet. 1997;349:1857–1863
  3. Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators (Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy). N Engl J Med. 2001;345:861–869
  4. Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group (Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes). N Engl J Med. 2001;345:851–860
  5. Agodoa LY, Appel L, Bakris GL, Beck G, et al. African American Study of Kidney Disease and Hypertension (AASK) Study Group (Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial). JAMA. 2001;285:2719–2728
  6. De Jong PE, Navis G, de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet. 1999;354:352–353
  7. Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia. 1994;37:511–516
  8. Apperloo AJ, de Zeeuw D, de Jong PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int Suppl. 1994;45:S174–S178
  9. Taguma Y, Kitamoto Y, Futaki G, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med. 1985;313:1617–1620
  10. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?. Kidney Int. 1994;45:861–867
  11. van Paassen P, de Zeeuw D, Navis G, de Jong PE. Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function. Nephrol Dial Transplant. 2000;15:637–643
  12. Schjoedt KJ, Rossing K, Juhl TR. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68:2829–2836
  13. de Zeeuw D, Remuzzi G, Parving HH. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int. 2004;65:2309–2320
  14. Lea J, Greene T, Hebert L. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med. 2005;165:947–953
  15. Atkins RC, Briganti EM, Lewis JB. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis. 2005;45:281–287
  16. Eijkelkamp WB, Zhang Z, Remuzzi G. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol. 2007;18:1540–1546
  17. Szeto C-C, Chow K-M, Kwan Ching-Ha B, et al. Oral Calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am J Kidney Dis. 2008;51:724–731
  18. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol. 2005;16:3038–3045
  19. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 2005;68:1190–1198
  20. Buter H, Hemmelder MH, Navis G, de Jong PE, de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant. 1998;13:1682–1685
  21. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int. 1989;36:272–279
  22. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G. Effects of Dietary Sodium and Hydrochlorothiazide on the Antiproteinuric Efficacy of Losartan. J Am Soc Nephrol. 2008;doi: 10.1681/ASN.2007060693
  23. Jacobsen PK. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II). J Renin Angiotensin Aldosterone Syst. 2005;6:55–68
  24. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003;361:117–124
  25. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005;68:2823–2828
  26. Abbott: A Study of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Being Treated With Renin-Angiotensin System Inhibitors. http://clinicaltrials.gov/ct2/show/NCT00421733Accessed March 28, 2008
  27. Gansevoort RT, de Zeeuw D, de Jong PE. Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease. Nephrol Dial Transplant. 1995;10:497–504
  28. Perico N, Remuzzi A, Sangalli F, Azzollini N, Mister M, Ruggenenti P, et al. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin. J Am Soc Nephrol. 1998;9:2308–2317
  29. Gambaro G, Kinalska I, Oksa A. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol. 2002;13:1615–1625
  30. Lambers Heerspink HJ, Fowler MJ, Volgi J, et al. Collaborative Study Group Rationale for and study design of the sulodexide trials in Type 2 diabetic, hypertensive patients with microalbuminuria or overt nephropathy. Diabet Med. 2007;24:1290–1295
  31. Bos H, Andersen S, Rossing P, De Zeeuw D, Parving HH, De Jong PE, et al. Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy. Kidney Int Suppl. 2000;75:S32–S37

PII: S0272-6386(08)00591-X

doi: 10.1053/j.ajkd.2008.03.013

American Journal of Kidney Diseases
Volume 51, Issue 5 , Pages 713-716 , May 2008

Article Tools